Nicola Pietrafusa

Rome, 00146, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 65 publications

Volumetric Absorptive Microsampling (VAMS) for Therapeutic Drug Monitoring of Antiseizure Medications (ASMs) in Pediatric Patients.

Volumetric Absorptive Microsampling (VAMS) for Therapeutic Drug Monitoring of Antiseizure Medications (ASMs) in Pediatric Patients.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: May 28, 2026

Neuropsychological functioning and progression in Lafora disease.

Neuropsychological functioning and progression in Lafora disease.

Journal: Epilepsia
Published: February 22, 2026

Comparative Effectiveness of Brivaracetam, Cenobamate, Lacosamide, and Perampanel in Focal Epilepsy.

Comparative Effectiveness of Brivaracetam, Cenobamate, Lacosamide, and Perampanel in Focal Epilepsy.

Journal: JAMA neurology
Published: February 09, 2026

Correction: Open-label evaluation of oral trehalose in patients with neuronal ceroid lipofuscinoses.

Correction: Open-label evaluation of oral trehalose in patients with neuronal ceroid lipofuscinoses.

Journal: Journal of neurology
Published: October 15, 2025

Gastrointestinal symptoms in neuronal ceroid lipofuscinoses (NCLs): an observational study on prevalence, timing of progression, and impact on quality of life.

Gastrointestinal symptoms in neuronal ceroid lipofuscinoses (NCLs): an observational study on prevalence, timing of progression, and impact on quality of life.

Journal: Neurogenetics
Published: September 18, 2025

Long-Term Open-Label Study Evaluating Oral Miglustat Treatment in Patients With Neuronal Ceroid Lipofuscinosis Type 3.

Long-Term Open-Label Study Evaluating Oral Miglustat Treatment in Patients With Neuronal Ceroid Lipofuscinosis Type 3.

Journal: Neurology
Published: September 09, 2025

Cost-effectiveness of fenfluramine as add-on treatment in the management of Dravet Syndrome: A real-world multicenter study.

Cost-effectiveness of fenfluramine as add-on treatment in the management of Dravet Syndrome: A real-world multicenter study.

Journal: Epilepsia open
Published: August 07, 2025

Fenfluramine in SCN1A-related GEFS+: A multicenter observational study on efficacy, EEG improvement, and tolerability.

Fenfluramine in SCN1A-related GEFS+: A multicenter observational study on efficacy, EEG improvement, and tolerability.

Journal: Epilepsia open
Published: May 09, 2025

Neurocognitive, behavioral, and treatment burden as key predictors of parental stress in pediatric epilepsy.

Neurocognitive, behavioral, and treatment burden as key predictors of parental stress in pediatric epilepsy.

Journal: Epilepsia
Published: April 28, 2025

Is highly purified cannabidiol a treatment opportunity for drug-resistant epilepsy in subjects with typical Rett syndrome and CDKL5 deficiency disorder?

Is highly purified cannabidiol a treatment opportunity for drug-resistant epilepsy in subjects with typical Rett syndrome and CDKL5 deficiency disorder?

Journal: Epilepsia open
Published: March 12, 2025

Fenfluramine treatment for Dravet syndrome: Long term real-world analysis demonstrates safety and reduced health care burden.

Fenfluramine treatment for Dravet syndrome: Long term real-world analysis demonstrates safety and reduced health care burden.

Journal: Epilepsia
Published: November 22, 2024

Open-label evaluation of oral trehalose in patients with neuronal ceroid lipofuscinoses.

Open-label evaluation of oral trehalose in patients with neuronal ceroid lipofuscinoses.

Journal: Journal of neurology
Published: May 28, 2024
Showing 1-12 of 65

Last Updated: 09/26/2026